Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)
The purpose of this study is to examine the effect of G-CSF on disease free survival and overall survival in aplastic anaemia patients who also receive ATG and Cyclosporin A.
Open label, randomized, controlled study of G-CSF, ATG and Cyclosporin A versus ATG and Cyclosporin A. Subjects will be evaluated for hematologic response through day 240. Subjects who do not demonstrate a partial or complete remission by day 120 will be randomized to receive either a second course of ATG or continue their current regimen. Subjects who do demonstrate a partial or complete remission will continue their current regimen through day 240 or maintenance of a complete remission for 30 days. The last day of study treatment will be day 240.
Allocation: Randomized, Control: Placebo Control, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
G-CSF, Early retreatment with ATG
St. Louis Hospital
European Group for Blood and Marrow Transplantation
Results (where available)
- Source: http://clinicaltrials.gov/show/NCT01163942
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
Methods to determine in patients the nature of a disease or disorder at its early stage of progression. Generally, early diagnosis improves PROGNOSIS and TREATMENT OUTCOME.
Early Detection Of Cancer
Methods to identify and characterize cancer in the early stages of disease and predict tumor behavior.
Early Growth Response Protein 1
An early growth response transcription factor that has been implicated in regulation of CELL PROLIFERATION and APOPTOSIS.
To assess the tolerability and effectiveness of rabbit antithymocyte globulin (ATG, Thymoglobuline) with ciclosporin in the first line treatment of patients with acquired severe aplastic a...
Estimate the efficiency of a strategy of premature screening of the maternal anaemia during the first quarter of pregnancy versus the usual strategy of screening of the anaemia during the...
The purpose of this study is to continue to optimize conditioning regimens in high-risk patients with severe aplastic anemia (SAA) transplanted with marrow from human leukocyte antigen (HL...
To quantify the role of drugs and other factors in the etiology of agranulocytosis and aplastic anemia.
The purposes of this study are threefold: 1) to evaluate the prevalence and risks of oral complications in patients with aplastic anemia; 2) to evaluate if oral problems in these patients...
Aplastic anaemia can coincide with non-A-E hepatitis. Treatment follows a standardised study protocol of the German Society of Paediatric Oncology and Haematology (GPOH). Patients receive immunosuppre...
In this interesting paper, "Decreased plasma cytokines associate with low platelet counts in aplastic anemia and immune thrombocytopenic purpura", Feng et al(1) follow on from earlier studies of cytok...
Allogeneic marrow transplantation offers curative therapy for children with severe aplastic anaemia (SAA). We report the outcomes of 148 children with SAA who received human leucocyte antigen (HLA)-ma...
Leguit R J & van den Tweel J G (2010) Histopathology The pathology of bone marrow failure An important indication for bone marrow investigation is the presence of bone marrow failure, which manifests...